NORTH CHICAGO, Ill., Oct. 20, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of ...
NORTH CHICAGO, Ill., Oct. 29, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from two replicate Phase 3 studies evaluating the safety and efficacy of upadacitinib (RINVOQ ...
Oct 20 (Reuters) - AbbVie (ABBV.N), opens new tab said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira in a head-to-head . AbbVie has been ...
For the second time in the last three weeks, AbbVie has revealed successful results from a phase 3 study of Rinvoq as a treatment for the hair-loss disease alopecia areata (AA). The second replicate ...
- Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of these treatments is clinically inadvisable and ...
In Study 1, both doses of upadacitinib achieved the primary endpoint, with 45.2% and 55.0% of patients treated with upadacitinib 15 mg and 30 mg, respectively, reaching 80% or more scalp hair coverage ...
AbbVie settles with generic Rinvoq hopefuls, shielding the immunology med's US stronghold until 2037
With Rinvoq and its sibling medicine Skyrizi having successfully picked up the sales torch in the wake of Humira’s tumble over the patent cliff, AbbVie is working to cover its legal bases so the ...
AbbVie has struck a deal with generic drugmakers aimed at extending patent protection for its blockbuster autoimmune drug Rinvoq well into the next decade. AbbVie on Thursday said it has settled ...
Shares of AbbVie ABBV rose over 4% to a record high on Thursday after the company announced that it had settled patent litigation with all generic manufacturers who had sought the FDA’s approval for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results